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Abstract
Background: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-
cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been
previously described with a direct comparison with the assessments according to the conventional RECIST1.1.
Methods: Fifty-six advanced NSCLC patients treated with nivolumab monotherapy after its Food and Drug
Administration (FDA) approval were retrospectively studied. Tumor burden was quantified on serial CT scans during
therapy using irRECIST1.1, which uses unidimensional measurements and includes new lesion measurements in
total tumor burden. Response assessments by irRECIST1.1 were compared with assessments by RECIST1.1.
Responses of individual lesions in different organs were also compared.
Results: Tumor burden change at best overall response ranged from −66.8 to +278.1% (median: +3.9%). Response rate
was 14% (8/56; 8 partial responses, 0 complete responses) by irRECIST1.1 and by RECIST1.1. Time-to-progression (TTP)
by irRECIST1.1 was longer than TTP by RECIST1.1 (median TTP: not reached vs. 1.9 months, respectively). No patients
experienced pseudoprogression during the study. Among 128 target lesions, the lesion-based size change at best
response differed significantly across different organs, with adrenal lesions and lymph nodes having greater size
decrease, followed by lung, while liver and other miscellaneous lesions had lesser degree of size decrease (p = 0.002).
Conclusions: Immune-related response evaluations using irRECIST1.1 in advanced NSCLC patients treated with
nivolumab resulted in the identical response rate and longer TTP compared to RECIST1.1. No pseudoprogression
cases were observed during the study. Adrenal lesions and lymph nodes were more responsive and liver lesions
were less responsive to nivolumab.
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Background
Programmed cell death (PD)-1 immune checkpoint in-
hibitors have emerged as promising treatment options
for multiple cancer types [1–11]. Two PD-1 inhibitors,
nivolumab and pembrolizumab, were recently approved
for treatment of advanced non-small-cell lung cancer
(NSCLC), resulting in widespread use in these agents in
the clinical setting. These agents have shown response
rates ranging from 14.5–19.4% in recent NSCLC trials
[4, 8, 9, 12, 13]. In two phase 3 studies of nivolumab for
NSCLC, a higher response rate and longer overall
survival (OS) were observed in nivolumab-treated pa-
tients compared to docetaxel-treated patients, both in
squamous NSCLC [14] and non-squamous NSCLC [12].
Another recent phase 3 study of pembrolizumab in
advanced NSCLC also showed a higher response rate
and longer OS in patients treated with pembrolizumab
compared to those treated with docetaxel [13].
Traditionally, the anti-tumor activity of a therapeutic
agent is assessed using the Response Evaluation Criteria
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in Solid Tumors (RECIST) guidelines, originally pub-
lished in 2000 and revised in 2009 as RECIST1.1, which
utilizes unidimensional, longest diameter measurements
to quantify tumor burden [15–17]. Response assessment
by RECIST1.1 is frequently used as a primary endpoint
in many clinical trials. According to RECIST1.1, patients
are categorized as having progressive disease (PD) when
their tumor burden increases above 20% and 5 mm
comparing to baseline, or when the appearance of new
lesions is noted [16, 17]. However, in patients treated
with immune-checkpoint inhibitors, unique radiographic
response patterns have been noted, such as a response
after an initial increase of tumor burden or a reduction
in tumor burden during or after the appearance of new
lesions, which would otherwise be classified as PD by
RECIST1.1 [18–20]. To capture these unconventional re-
sponse patterns termed “pseudoprogression”, a novel set
of criteria, immune-related response criteria (irRC) was
proposed in 2009 [20]. The key features of irRC are 1)
inclusion of new lesion measurements to the total tumor
burden and 2) requirement of confirmation of PD on two
consecutive scans at least 4 weeks apart [18–20]. Subse-
quently, irRC has been applied in trials of immune check-
point inhibitors in NSCLC and melanoma to define trial
endpoints [21–23].
Although irRC has introduced the novel important
concepts of immune-related response assessment, there
are issues that remain to be solved. A major methodo-
logical issue is that irRC uses bidimensional measure-
ments derived from a product of the longest diameter
and the longest perpendicular diameter as proposed in
WHO criteria back in 1981 [24], while most trials in
solid tumors over the past decade have been based on
RECIST and thus used unidimensional measurements
[18, 20]. It is therefore difficult to directly compare the
results obtained by using irRC versus RECIST, within
the same trial cohorts and across the different trials;
some differences may be simply due to the difference
from unidimensional versus bidimensional measures,
and may not reflect the difference in tumor burden dy-
namics such as the occurrence of immune-related tumor
response phenomena or the different magnitude of re-
sponses to different agents [19, 25, 26].
To overcome this methodological issue of immune-
related response evaluations, a prior study of ipilimumab
in melanoma assessed unidimensional irRC utilizing the
longest diameter measurements as in RECIST, and demon-
strated that unidimensional irRC provides highly concord-
ant response assessment compared to bidimensional irRC
with less measurement variability [26]. Another study
further incorporated the revised features of RECIST1.1 into
unidimensional irRC, such as the decrease in the number
of target lesions and the use of short axis measurements
for lymph nodes, and demonstrated high concordance of
response assessments [25], proposing a direction toward
immune-related RECIST1.1 (irRECIST1.1) to evaluate
anti-tumor activity of immune-checkpoint inhibitor ther-
apy in solid tumors [19, 25].
Although there is an increasing recognition of the
modified strategies such as irRC and irRECIST1.1 that
are specifically designed to address the immune-related
response phenomena, most current immunotherapy tri-
als rely on conventional RECIST1.1 to obtain standard-
ized endpoints that have been used as the basis for FDA
approval. Of note, immune-related response evaluations
in comparison with RECIST1.1 are not described in the
recent trials of PD-1 inhibitors in NSCLC, and there is
very limited data about the frequency of immune-related
response phenomena such as pseudoprogression in ad-
vanced NSCLC patients [27]. Lack of such information
may lead to challenges in the treatment decisions in pa-
tients with tumor burden increase during PD-1 inhibitor
therapy in the clinical setting, where oncologists need to
decide if they continue therapy for the possibility of
pseudoprogression, or change to alternate therapies for
the possibility of true progression. The challenges can be
particularly significant when FDA-approved commercial
agents are administered, as treatment discontinuation
decisions are not guided by specific trial protocols that
can help determine which criteria to use in tumor bur-
den assessments and when to consider terminating ther-
apy. This unmet clinical need has provided a motivation
to systematically investigate tumor response characteris-
tics of advanced NSCLC patients treated with commer-
cially prescribed PD-1 inhibitor therapy, as an initial
step to further address this emerging challenge in lung
cancer treatment.
The purpose of the present study is to evaluate tumor
response characteristics using irRECIST1.1 in advanced
NSCLC patients treated with nivolumab in the clinical
setting after its FDA approval, and compare the results
with those obtained by the conventional RECIST1.1.
Results and discussion
The demographics and disease characteristics of the 56
patients are summarized in Table 1. Median time on
therapy was 3.8 months (95%CI: 2.6–4.2). Median follow-
up time was 3.8 months (95%CI: 3.2–4.2). Twenty-one
patients (38%) were still on nivolumab therapy at the time
of analysis.
Response assessment by irRECIST and RECIST1.1
Tumor burden changes in reference to baseline (%) at
the time point of best overall response in 56 patients
ranged from −66.8 to +278.1% (median: +3.9%) (Fig. 1).
Response rate was 14% (8/56; 8 PR, 0 CR), which was
identical between irRECIST1.1 and RECIST1.1. Discord-
ance of BOR between irRECIST1.1 and RECIST1.1 was
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noted in 20 patients, in which BOR was SD by irRE-
CIST1.1 but was PD by RECIST1.1. Among these 20
patients, 10 did not have a confirmation of PD. Of these, 8
patients had no subsequent scans, and 2 patients had one
subsequent scan again demonstrating progression; how-
ever these scans were performed less than 4 weeks from
the previous scan, and no further scans were performed
thereafter. In the remaining 10 patients, new lesions were
included in the measurements by irRECIST1.1 rather than
immediately defining PD. TTP by irRECIST1.1 (irTTP)
was longer than TTP by RECIST1.1 (median TTP: not
reached vs 1.9 months, respectively) (Fig. 2). There were
no significant differences in demographics or disease
characteristics between responders and non-responders
(p > 0.29) (Table 1).
The tumor burden changes during nivolumab therapy
using irRECIST1.1 are demonstrated in the spider plot
(Fig. 3). None of the patients in this study demonstrated








Sex Male 31 (55%) 5 26 0.72
Female 25 (45%) 3 22
Age (years) Median (range) 65 (43–91) 62 (44–74) 65 (43–91) 0.29
Race White 49 (88%) 8 41 1.00
Black 3 (5%) 0 3
Asian 2 (3.5%) 0 2
Other 2 (3.5%) 0 2
Smoking Never 10 (18%) 1 9 1.00
Former 27 (48%) 4 23
Current 19 (34%) 3 16
Histology Adenocarcinoma 40 (71%) 6 34 0.59
Squamous cell carcinoma 9 (16%) 2 7
NSCLC NOSb 7 (13%) 0 7
airRECIST1.1 and RECIST1.1 have resulted in the same 8 responders
bNSCLC NOS = non-small-cell carcinoma not otherwise specified
Fig. 1 Waterfall plot of tumor burden change at best overall response in 56 patients. Two patients marked by * had greater than 200% (+219%
and +278%). Dashed lines represent the thresholds for partial response (−30%) and progressive disease (+20%)
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pseudoprogression at the time of analysis, defined as ini-
tial increase of tumor burden followed by subsequent
response.
New lesions during nivolumab therapy
Eighteen patients (18/56; 32%) developed new lesions
during therapy. Among them, 9 patients developed new
target and non-target new lesions, 2 patients developed
new target lesions alone, and 7 patients developed new
non-target lesions alone. In the 11 patients with new
target lesions, the number of new target lesions ranged
from 1–4 per patient (median: 2). The most common
location of new target lesions was the liver, noted in 7
patients, followed by lymph nodes (3 patients), adrenal
gland (2 patients), and lung (1 patient). Among new
non-target lesions, liver was the most common site
(noted in 7 patients), followed by lung (3 patients), lymph
nodes (3 patients), brain (2 patients), bone (2 patients),
and bowel (1 patient).
At the time of appearance of new lesions, no patients
met the criteria for partial response by irRECIST. How-
ever, 8 of the 18 patients with new lesions had SD (with
less than 20% increase) based on the irRECIST measure-
ments at the time of appearance of new lesions; of these,
6 patients had new non-target lesions only, and 2
patients had both new target and non-target lesions. In
the remaining 10 patients, the irRECIST measurements
showed PD (with at least 20% increase); of these, one
patient had new non-target lesions alone, 2 patients had
new target lesions alone, and 7 patients had new target
and non-target lesions.
Of the 18 patients, 5 patients had follow-up scans after
the appearance of new target lesions. None of the new
lesions showed response during the follow-up period of
this study. In 4 patients, new lesions progressed with
≥20% and 5 mm increase on their first follow-up scan
comparing to the size when they appeared; in one pa-
tient, new lesions showed stable disease on the first
follow-up scan, followed by disease progression on the
subsequent scan. Additional 3 patients with new non-
target lesion alone had follow-up scans, which showed
“stable disease” (non-CR, non-PD) for these lesions.
Among the remaining 10 patients who had no follow-up
scans after the appearance of new lesions, nivolumab
therapy was ended in 8 patients while 2 patients were
still on therapy at the time of analyses.
Lesion-based response assessment
A total of 128 target lesions were present in the cohort
of 56 patients at baseline (median 2 lesions per patient),
including 56 lung lesions, 31 lymph nodes, 16 liver le-
sions, 14 adrenal lesions, and 11 other lesions in miscel-
laneous locations. Thirty-five patients (62.5%) had more
than one lesion in the same organ, and 4 of them had
multiple lesions in two organs. The most common organ
with multiple target lesions was lung, noted in 16
patients, followed by lymph (10 patients), liver (7 pa-
tients), adrenal gland (4 patients), and other (2 patients)
(Additional file 1).
Lesion-based tumor size change (%) at best response
of each lesion was significantly different across the organ
categories(Kruskal-Wallis p = 0.002). Adrenal lesions and
Fig. 2 Time to progression by irRECIST and RECIST1.1
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lymph nodes had greater shrinkage, followed by lung,
while liver and miscellaneous lesions had less shrinkage
(Figs. 4, and 5). The response rates also significantly dif-
fered among the lesion groups according to the location
(Fisher p = 0.004). The response rate was highest in
adrenal gland lesions (6/14; 43%) followed by lymph
nodes (11/31; 35%), while the rates were lower in lung
(5/56; 9%), liver (2/16; 12%), and miscellaneous (1/11;
9%) lesions.
Discussion
The present study describes the initial results of tumor
response characteristics using irRECIST1.1 among
advanced NSCLC patients treated with commercially-
prescribed nivolumab in the clinical setting, and
provides a direct comparison of the assessment results
between irRECIST1.1 and RECIST1.1. The response rate
in this cohort was 14% both by irRECIST1.1 and by
RECIST1.1. No patient experienced pseudoprogression
during the study period. Lesion-based assessment showed
significant differences of responses across organs, with
adrenal lesions and lymph nodes being more responsive
and liver lesions being less responsive to therapy. To our
knowledge, this is the first study that demonstrated the
organ-specific tumor responses in patients treated with
immune checkpoint inhibitors.
The overall response rate of 14% in the present study
is similar to prior clinical trials of nivolumab or pembro-
lizumab in NSCLC, where response rates of 14.5–19.4%
were reported [4, 8, 9, 12]. All responders in the present
cohort had PR and no patient achieved CR; this is also
similar to clinical trial results, where CR was noted in 0
of 117 nivolumab-treated squamous NSCLC patients [4],
in 0.8% among 495 pembrolizumab-treated NSCLC
patients [9], and 1% among 292 nivolumab-treated non-
squamous NSCLC patients [12]. Tumor burden change
at BOR per patient had a wide range (−66.8 to +278.1%)
with a median of 3.9% in the present study, indicating a
wide range of responses and an apparent heterogeneity
of sensitivity to PD-1 inhibitors among advanced
NCCLC population as noted in the trials [4, 8, 12].
Demographics and clinical characteristics including
Fig. 3 Spider plot of tumor burden changes during nivolumab therapy using irRECIST. Longitudinal changes of tumor burden during therapy are
shown in reference to baseline, showing baseline tumor burden as 1.0. The scan time points with the appearance of new target lesions are
indicated by larger markers
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histology and smoking history showed no association
with response to nivolumab. In the recent two trials of
PD-1 inhibitor, the response rate was similar between
squamous and nonsquamous NSCLC [8, 9], which is
consistent with our results. Smoking history was associ-
ated with a higher rate of response to nivolumab in a
phase 1 study [8]; however, such observation was not
noted in our cohort, likely due to our small sample size.
Other molecular markers such as PD-L1 positivity of
tumor tissue were not available in most patients in this
clinical retrospective cohort.
Head-to-head comparisons between immune-related
response evaluations and the conventional RECIST
assessments are lacking in most of the trials of immune-
checkpoint inhibitor therapy, as recently described by
Chiou et al. [27]. Therefore, providing such comparisons
was one of the major goals of the present study. Assess-
ment of PR was fully concordant between irRECIST1.1
Fig. 4 Waterfall plot of lesion-based tumor size change at best response of 128 target lesions classified by the organs. The graph shows changes
of lung lesions in blue bars, lymph nodes in yellow, adrenal lesions in purple, liver lesions in red, and other miscellaneous lesions in green bars
Fig. 5 Lesion-based tumor size change at best response of 128 target lesions classified by the organs. The black horizontal line shows a median value for
the lesion-based shrinkage in each organ. The gray vertical line with horizontal bars at the upper and lower ends represents the 1st and 3rd quartiles
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and RECIST1.1, in this cohort with no cases of pseudo-
progression. The discordance of BOR assessment be-
tween two criteria was only noted between SD and PD,
either because of the requirement of confirmation for
PD or the inclusion of new lesions in the total tumor
burden by irRECIST1.1, which contributed equally to
the discordance of BOR. These two features of irRE-
CIST1.1 also contributed to longer TTP by irRECIST1.1
(irTTP) compared to TTP by RECIST1.1, which is an
expected consequence of immune-related response
evaluations as reported in a prior study of melanoma
patients treated with ipilimumab [25]. Median TTP by
RECIST1.1 was 1.9 months in the present cohort; in
spite of the relatively short follow-up period of the
present study, the result is overall similar to the previous
studies in the trial cohorts reporting median PFS of 1.9-
3.7 months based on RECIST [4, 8, 9, 12]. The present
study focused on TTP, rather than PFS, as its major
purpose was the differences derived from two tumor
response criteria, which TTP reflects most accurately
and is not affected by death as an event.
Pseudoprogression, or initial progression with tumor
burden increase followed by subsequent response, is a
challenging phenomenon during immune checkpoint
inhibitor therapy. None of the patients in the present
study experienced pseudoprogression during the treat-
ment period of the study, which can be due to the small
number of patients studied in a relatively short period of
time during this initial clinical experience. In a phase 1
study of nivolumab in advanced NSCLC, 5% (6/129) of
the patients experienced pseudoprogression, which were
within 20 weeks since initiation of therapy [8]. On the
other hand, a recent study et al. in 44 NSCLC patients
treated with trials of PD-1 and PD-L1 inhibitors, 4 pa-
tients (9%), all of whom received PD-L1 inhibitors, had
experienced pseudoprogression at 3 months of therapy
[28]. Further investigations are needed in larger cohorts
to determine the exact incidence of pseudoprogression
in advanced NSCLC patients subclassified according to
the types of immune-checkpoint inhibitors used in the
treatment regimen.
The appearance of new lesions presents another man-
agement dilemma during immune-checkpoint inhibitor
therapy because it may indicate true progression or
pseudoprogression. In the present study, one-third of
patients developed new lesions, most commonly in the
liver. Though no patients showed partial response based
on irRECIST measurements at the time of appearance of
new lesions, 44% of the patients (8/18) had measureable
tumor burden changes within the range of SD. Notably,
2 of these patients had new target lesions and had SD
even though the measurements of these new lesions
were added to the total tumor burden. These observa-
tions are indicative of the merit of the use of irRECIST
for detection of stable disease in the setting of appear-
ance of new lesions.
Most patients with follow-up scan after the appearance
of new lesions showed progression of new lesions, and
none of the new lesions subsequently responded during
therapy. Though very few reports describe the detailed
locations and behaviors of new lesions during immune-
checkpoint inhibitor therapy, in a recent study by
Caramella et al., 3 of the 4 patients with pseudoprogres-
sion had new lesions in the chest (2 in the lung and one
in the mediastinum) during PD-L1 inhibitor therapy
[28]. Precise descriptions of new lesion location and its
behavior during therapy are needed in future studies to
further understand the phenomenon of pseudoprogres-
sion in the setting of new lesions, and to differentiate it
from true progression for better treatment guidance.
Lesion-based response assessment resulted in notable
differences in the response rate and the degree of tumor
size decrease across anatomic organs of the lesions.
Adrenal lesions and lymph nodes are more responsive
with a greater tumor size decrease, while liver lesions
were less responsive with less size decrease. Although
the exact mechanisms of this observation are uncertain,
it may indicate the impact of different tumor microenvi-
ronments in different organs on immune-related tumor
response. The liver has an intrinsic immune suppressive
microenvironment [29, 30], which may help tumors to
escape from anti-tumor immune attacks during therapy,
resulting in less tumor shrinkage. Lymph nodes as
source organs of immune cells may be at least partly
contribute to the observed greater response of lymph
nodes as target lesions. Adrenal gland is one of the most
common site of extrathoracic metastasis from NSCLC,
and is also a major effector organ of hypothalamic–pitu-
itary–adrenal (HPA) axis and is responsible for synthesis
and action of cytokines [31, 32]. Therefore, the organ is
known to have immune-modulating properties via acti-
vation of the HPA axis as well as via cell-cell mediated
immune-adrenal interactions [31, 32]. The unique prop-
erties of the organ may be related to a greater degree of
response in adrenal lesions.
To our knowledge, lesion-based immune-related re-
sponses across different organs have not been previously
described in detail in NSCLC patients. Given the signifi-
cant difference of responses across different organs
noted in this study, lesion-based analysis may provide
clinically significant information because the anatomic
distribution of metastasis and selection of target lesions
prior to therapy may affect the response outcome. Fur-
ther investigations are needed to study the consistency
of the observations in larger cohorts of NSCLC and to
understand the underlying mechanisms. Notably, the re-
sults of a recent investigation by Ribas et al. in advanced
or metastatic melanoma treated with pembrolizumab in
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phase 1b trials indicate that the response rate may be
higher in patients with lung metastases (M1b disease)
than in those with other visceral metastases (M1c dis-
ease) [33]. Another study in 337 melanoma patients
treated with pembrolizumab or nivolumab demonstrated
that patients with liver metastases were less likely to re-
spond to treatment, while patients with lung metastases
were more likely to respond [34]. These results and the
observations in the present NSCLC study are similar in
that patients with liver metastases are less likely experi-
ence tumor response, which is consistent with the
immunosuppressive environment in the liver. The pres-
ence of lung lesions was not indicative of response in
our cohort as opposed to the studies in melanoma,
which is likely due to the presence of primary lung
tumor in many of the advanced NSCLC patients. It is
necessary to further investigate the similarities and dif-
ferences of lesion-based responses across different tumor
types, to understand if the differences are due to tumor
microenvironment alone or are also related to the inter-
actions between tumor and its microenvironment.
A limitation of the study includes the small number of
patients treated at a single institution during the initial
clinical experience studied with a retrospective design.
However, such study design allowed us to report the
evaluation of tumor response characteristics in NSCLC
patients treated with commercially-prescribed nivolu-
mab in a “real-world” setting, which has not been stud-
ied in detail despite an abundance of published data
from prospective trials [4, 8, 9, 12]. Lack of molecular
markers such as PD-L1 tissue staining in most patients
in this clinical cohort limits the assessment of predictive
values of such markers. Short follow-up time in this
initial clinical experience also limits the evaluation of
late responses and durable stability of the disease. These
issues as well as the prognostic values of irRECIST1.1
assessments remain to be investigated with more mature
follow-up data in a larger number of patients.
Conclusion
In conclusion, the present study described tumor response
characteristics in advanced NSCLC patients treated clinic-
ally with nivolumab monotherapy using irRECIST1.1, with
a direct comparison with the conventional RECIST1.1
assessments. Response rate was identical between the two
criteria, and no cases of pseudoprogression were observed
during the treatment period of the study. Although a small
percentage of pseudoprogressors were noted in the PD-1
inhibitor NSCLC trials, pseudoprogression appears to be a
rare phenomenon in lung cancer. Inclusion of new lesions
is a key component for future development of immune-
related response evaluations to further understand their
implications for treatment decisions both in trials and
clinical practice. Responses of individual organs were
different across anatomic organs, where adrenal lesions
and lymph nodes were most responsive and liver lesions
were least responsive to nivolumab. Further studies are
needed to identify predictive and prognostic markers for
immune-checkpoint inhibitor therapy and to address
long-term effect of PD-1 inhibitor therapy on immune-
related response characteristics in NSCLC.
Methods
Patients
The study population included 56 advanced NSCLC pa-
tients treated with nivolumab monotherapy at the Dana-
Farber Cancer Institute after its FDA approval between
March and August 2015 as a part of their standard
clinical care. All patients had baseline CT prior to the
initiation of nivolumab therapy, and at least one follow-
up CT during therapy available for review. Nivolumab
was administered at a dose of 3 mg/kg given intraven-
ously every two weeks. Medical records and imaging
studies were reviewed.
Tumor burden measurements on the longitudinal scans
Baseline and all follow-up CT scans during nivolumab
therapy were reviewed for the assessment of tumor
burden by a board-certified radiologist (M.N.). Tumor
burden was quantitatively assessed using irRECIST1.1
based on the previously published studies [19, 25, 26]. In
brief, target lesions (≥10 mm in the longest diameter for
non-nodal lesions and ≥15 mm in short axis for nodal
lesions) were selected on baseline scans, allowing up to
2 lesions per organ and up to 5 lesions in total, as in
RECIST1.1 [15–17]. Measurements of target lesions
were performed on baseline and all follow-up CT scans
during therapy. If new lesions appeared on the follow-up
scans, the measurements of the new lesions were
included in the sum of the measurements, as this has
shown to be an important feature of immune-related re-
sponse evaluations [18, 20, 25, 26]. Up to 2 new lesions
per organ and 5 new lesions in total were allowed at
each time point [20, 25]. New lesions had to be measur-
able (≥10 mm in the longest diameter for non-nodal le-
sions and ≥15 mm in short axis for nodes) to be
included in the sum of the tumor measurements [25].
Measurable new lesions that were included in the mea-
surements were recorded as “new target lesions”, and
others lesions (i.e., non-measurable new lesions) were re-
corded as “non-target new lesions”. Other imaging stud-
ies such as brain MRI and PET/CT scans were also
reviewed to identify new lesions and assess non-target
lesions [35]. Conventional RECIST1.1 assessment was
also performed. Follow-up scans were performed per
treating providers’ discretion as a part of clinical care
without predefined intervals.
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Tumor response assessment according to irRECIST1.1 and
RECIST
Best overall response by irRECIST1.1 (irBOR) during ther-
apy was assigned to each patient, using the thresholds of
≥30% decrease compared to baseline for partial response
(PR) and ≥20% increase compared to nadir for progressive
disease (PD), based on the prior studies showing the high
concordance among the different methods of immune-
related response evaluations [19, 25, 26]. Confirmation on 2
consecutive scans at least 4 weeks apart was required for
irPD [18, 20, 25, 26]. Time to progression using irRE-
CIST1.1 (irTTP) was obtained in each patient, allowing the
inclusion of new lesion measurements and requiring con-
firmation of PD [25, 26]. As a comparison, BOR and TTP
according to the conventional RECIST1.1 was also defined
in each patient, where the appearance of new lesions or
tumor burden increase ≥20% and 5 mm compared to base-
line immediately defined PD without requiring confirm-
ation [16, 17]. For both criteria, TTP was measured from
the date of initiation of therapy to the date of progression
as defined by the criteria. Unlike PFS, TTP does not include
death as an event that defines the endpoint. Complete
response (CR) required disappearance of all lesions, except
for lymph nodes that need to be less than 10 mm in short
axis, for both RECIST and irRECIST1.1 [18, 20, 25, 26].
Lesion-based response assessment
Tumor measurements were further reviewed to assess
responses of each target lesion. The same thresholds for
response and progression for the total tumor burden
(≥30% decrease for PR and ≥20% and 5 mm increase for
PD) were applied for the lesion-based assessment. Each
lesion was categorized according to the organs where it
was located, including lung, lymph node, adrenal gland,
liver, and other. Tumor size change in reference to base-
line (%) and best response of each target lesion were
compared across the anatomic organ categories.
Statistical analysis
Comparison across groups was performed using a Fisher
exact test for categorical variables and a Kruskal-Wallis
test for continuous variables. TTP was estimated using a
Kaplan-Meier method. All p values are based on a two-
sided hypothesis. A p value of less than 0.05 was consid-
ered to be significant.
Additional file
Additional file 1: The distribution of the number of target lesions
according to the locations in patients grouped by irBOR. (TIF 7641 kb)
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